All news coverage featuring Synthace.
For more information or to request a press pack, contact our Head of PR, Courtney Glymph.
Aug 2021- Artificial intelligence has been hailed as the next big thing in drug discovery but to leverage its full potential, the life sciences industry first needs to pay attention to experimental design and data collection.
Aug 2021- Forbes covers the release of the Synthace Life Sciences R&D Cloud, the first no-code software platform for automating experimentation and insight sharing. Read on to learn more about how our platform is transforming life sciences R&D.
Aug 2021- BioSpace announces the release of the Synthace Life Sciences R&D Cloud in the Global Roundup.
Aug 2021- Our CEO Guy Levy-Yurista discusses the barriers to innovation life scientists currently face and the importance of effective automation and software tools to support powerful experimentation and rapid, confident decision-making.
Aug 2021- Synthace has developed a ‘no-code’ cloud platform for life sciences R&D which addresses complexity, speed and reproducibility for scientists while lowering the barrier to automated biological experimentation and insight sharing.
Aug 2021- Synthace announces the first life sciences R&D cloud that includes a no-code software platform addressing the largest barriers to innovation that R&D life scientists currently face.
Jun 2021- As biopharmaceutical products have become increasingly complex, we need a new way of working. Synthace's CSO and co-founder, Markus Gershater, looks at how automation and AI can transform pharma R&D.
May 2021- BioWorld™ recognizes Synthace among the latest new hires and promotions in the med-tech industry.
May 2021- Synthace Ltd announces the appointment of Guy Levy-Yurista as Chief Executive Officer (CEO) and Board Member to guide the company through its next stage of growth.
Apr 2021- Oxford Biomedica is optimizing its vector production system to boost yields and accelerate production in response to growing demand. The company is working with Synthace and Microsoft to better understand vector production to improve yield and quality and remove steps that are not needed.
Apr 2021- The digitalization of bioprocessing technology isn’t happening for its own sake, but to ensure that outsourced manufacturing tasks will be part of highly integrated processes. Synthace's Corporate Strategy Manager, Dr Peter Crane, comments on the topic.
Mar 2021- A novel combination of miniaturized purification technology, automation and software presents an opportunity to drastically shorten drug/vaccine development timelines. Synthace's senior automation engineer, Dr Arne Vandenbroucke, comments on the topic.
Mar 2021- Strong financial performance and the achievement of other key milestones demonstrate the growing strength of Synthace’s offering within the biopharma and biotech industries.
Mar 2021- Dr. Jurascheck brings with him more than twenty years of experience spanning senior technology roles in high-tech product companies and consultancies.
Mar 2021- Bioassays are vital to QA/QC, preclinical studies & clinical testing but are challenging to perform. Lab automation offers solutions but comes with its own challenges. Expert Milena Stanković-Brunner comments on the topic in this BioProcess International article.
Feb 2021- The COVID-19 pandemic has revealed the fragility of the international bioeconomy to a world fractured along geopolitical lines. Dr Peter Crane, our Corporate Strategy Manager, asks whether revolutionizing our CDMOs may be vital to building a more robust and responsive bioeconomy.
Feb 2021- The podcast with our CSO Markus Gershater is listed as one of the most popular podcasts for 2020 in Cell Culture Dish. Markus talked about Computer-Aided Biology and how it addresses biomanufacturing challenges, and discussed ways to build a common culture between science and software.
Jan 2021- With the rising demand for cell and gene therapies, the need for manufacturing innovation has never been higher. Check out this great article featuring insights from Peter Crane, our Corporate Strategy Manager.
Jan 2021- Scientific Computing World features insights from Synthace's CSO Markus Gershater on the gaps in lab digitization & the tools used by leading life sciences companies to bring the vision of seamless digitization closer to life.
Jan 2021- Engitix joins other leading life-sciences businesses – including Synthace, GammaDelta and Mapletree – on the fourth floor of The WestWorks building in White City, London, UK. This scientific endeavour is taking place in an office building that previously housed the BBC.
Nov 2020- Scientific Computing World recognizes Antha's DOE capabilities and presents Synthace's collaboration with Oxford Biomedica.
Nov 2020- Ipsen has teamed up with Synthace to ramp up the development of new treatments targeting secretion in a wide range of diseases, including oncology, endocrinology, pain management and rare disease.
Nov 2020- Ipsen has automated design and construction of therapeutic candidates using Synthace’s integrative software platform, Antha.
Oct 2020- Antha now allows researchers to flexibly design and execute automated ELISA protocols and automatically gather, structure, and analyze the data.
Oct 2020- Synthace develops an innovative new approach to automating the ELISA
Sep 2020- In this podcast, Synthace's CSO and co-founder Markus Gershater explains Bioprocessing 4.0, presents some of our case studies, discusses the vision for computer-aided biology, and more.
Sep 2020- Just as computer-aided design (CAD) ushered in the Information Age, Synthace’s CEO, Tim Fell, wants to use computer-aided biology (CAB) usher in a new era in biology.
Aug 2020- Co-authored by Synthace's CEO Tim Fell, the article highlights how the COVID-19 crisis revealed the dire need for digitization of the biology lab, and how automation can transform R&D moving forward.
Jun 2020- Dr David Cox discusses how the COVID-19 pandemic is likely to accelerate the growing demand for lab automation & remote drug development, with expert comments from Arctoris, Synthego, and Synthace’s Dr Peter Crane.
Jun 2020- Synthace’s field application scientist Emilie Fritsch talks about Synthace’s collaboration with Microsoft Research that has used the Design-Build-Test-Learn (DBTL) approach and the Antha platform to create artificial genetic pathways.
May 2020- A growing cadre of startups is pursuing iterative cycles of machine learning, wet-lab experimentation and human feedback to accelerate target drug discovery.
Apr 2020- Synthace's Senior Automation Engineer Arne Vandenbroucke talks about our experience with Innovation AveNEW at SLAS 2020.
Mar 2020- Bdaily looked at what companies in the North East, Yorkshire and London are doing to support individuals and groups during the COVID-19 pandemic.
Mar 2020- Synthace is offering Antha “pro-bono” to any teams working on COVID-19 therapeutics discovery, diagnostics or production optimization.
Nov 2019- Why increasingly precise or high-throughput experiments need specialized hardware and software solutions.
Nov 2019- Automation cannot, and will not, replace scientists in the lab of the future. People are integral. As Technology Networks explains.
Oct 2019- Featured as a notable technology that demonstrates the industry’s dedication to finding new ways to help manufacturers shorten time to market.
Aug 2019- How augmented and assistive technologies could enhance the scientist and provide the first step towards a data science-led future for biopharma.
Jul 2019- Synthace features in this article about putting the power of computation in the biologist’s hand.
Jul 2019- Forbes highlights our mission to not just digitize the lab, but to revolutionize the way biology is done with one simple idea: a universal language.
May 2019- Featured as one of the companies at the heart of the evolution in biological software.
May 2019- Is augmented intelligence the key to achieving true digital transformation in pharma? Peter Crane outlines the need for a scientist-centric approach.
Apr 2019- Synthace features in this article in the Economist in which Oliver Morton states that Synthetic biology has only just begun.
Mar 2019- Microsoft joins forces with Synthace, Oxford Biomedica and Princeton University to build an end-to-end platform for programming the biology of living cells.
Dec 2018- Synthace closed a $25.6m Series B financing in the round led by Horizons Ventures, with participation from Luminous Ventures, SOSV, and select other individual and large family office investors.
Dec 2018- Synthace raised $25.6 million in a series B funding round, following a $9.6 million series A raise in September 2017, which brought Synthace’s total venture capital haul to $35.2 million.
Dec 2018- Synthace’s CEO Tim Fell, Patrick Zhang from Horizons Ventures, and Synthace’s Chairman Bob Wiederhold comment on the closing of the $25.6m Series B financing round.
Dec 2018- The $25.6m Series B financing will be used to further expand Synthace’s product capabilities and fuel company growth.
Nov 2018- Synthace is one of the companies leading Europe’s growth in the new technologies and business models category.
Oct 2018- Synthace’s Computer-Aided Biology whitepaper lays out the most complete industry vision to date for how biological research will be transformed by an emerging ecosystem of tools.
Oct 2018- Synthace announces the release of a new comprehensive whitepaper entitled “Computer Aided Biology: Delivering Biotechnology in the 21st Century”.
Aug 2018- Synthace appointed Merck's Susan Shiff to its board of directors.
Jul 2018- Synthace has taken up office space at the former BBC office in White City Place.
Jun 2018- Synthace has been recognized in Gartner, Inc.’s “Cool Vendors in Life Sciences” report for its Laboratory of the Future Platform.
